Recombinant therapeutic proteins are high-value biopharmaceuticals for which the demand continues to increase dramatically.
To produce these proteins requires cost-effective and advantageous expression hosts, which allow for dedicated genetic engineering of a given protein. In general, plants are considered superior hosts in terms of safety as they do not serve as vehicles for human viruses or TSE.
At Phyton, our plant cells are cultivated under controlled conditions avoiding any animal-derived media components, thus further improving safety. In addition, plant cell cultures, and their industrial application within our PCF® process, are highly reliable means of commercial production which is not affected by environmental factors.
Phyton has developed a plant cell line – The Universal Host™ – which provides favourable conditions for the manufacture of both complex and unmodified proteins. Phyton has the world’s largest BSL-1-approved bioreactor cascade in place (7500 L) authorized for use with genetically engineered plant cells. Phyton has extensive expertise and know-how in genetic engineering with special emphasis on complex proteins. The Universal Host™ can also be applied in the metabolic engineering of a diverse range of secondary metabolites.